Sangamo Therapeutics shares fall 1.56% in after-hours after reporting positive topline results from Phase 1/2 STAAR study.

Sangamo Therapeutics, Inc. fell 1.56% in after-hours trading, following the release of positive topline results from its registrational Phase 1/2 STAAR study, which showed an average eGFR slope of 1.965 mL/min/1.73m²/year in 32 Fabry disease patients. The FDA has agreed to use eGFR slope as an intermediate clinical endpoint for accelerated approval, with the company planning to submit a BLA in the first quarter of 2026. Additionally, HC Wainwright & Co. reiterated its 'Buy' rating for Sangamo with a target price of $10.00.